サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1477979

結核菌治療市場：製品タイプ別、エンドユーザー別、地域別 - 世界の産業分析、規模、シェア、成長、動向、予測、2024年～2032年

Mycobacterium Tuberculosis Treatment Market by Product Type, End-Users, and Geography (North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa): Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2032

出版日
ページ情報
英文 287 Pages
納期
2～5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
結核菌治療市場：製品タイプ別、エンドユーザー別、地域別 - 世界の産業分析、規模、シェア、成長、動向、予測、2024年～2032年
出版日: 2024年05月03日
発行: Persistence Market Research
ページ情報: 英文 287 Pages
納期: 2～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

Persistence Market Research社の結核菌治療市場調査レポートでは、2024年から2032年にわたる市場動向、成長促進要因・課題、将来的な技術革新を詳細に分析しています。市場の現状と将来予測に関する洞察を提供します。

結核菌治療薬の世界市場は、2024年の21億3,000万米ドルから2032年には24億米ドルへと、CAGR1.2％を達成すると予測されます。

主な洞察

  • 推定市場規模（2024年）：21億3,000万米ドル
  • 予測市場規模（2032年）：24億米ドル
  • 世界市場成長率（CAGR 2024年～2032年）：1.2%

結核菌治療市場 - レポート範囲：

結核菌は結核を引き起こす細菌であり、主に肺を侵すが、他の臓器に侵入することもあります。本レポートでは、世界の結核患者の増加、結核研究への資金提供の増加、診断技術の強化など、結核菌治療への需要を促進する要因に焦点を当てています。

市場促進要因：

結核菌治療の需要は、いくつかの要因によって高まっています。世界の結核患者の増加、スクリーニングや診断手段の強化、より即効性があり効果的な薬剤レジメンの開発などが、この成長の原動力となっています。薬剤耐性結核の増加は、併用療法や長期的なワクチン戦略など、新たな治療アプローチの研究に拍車をかけています。さらに、世界の保健活動への取り組みや結核プログラムへの資金提供が、市場拡大を大きく後押ししています。

市場の抑制要因：

結核菌治療市場は、先進的な結核菌治療薬の高コスト、低所得国における医療施設へのアクセスの制限、治療不遵守率の高さなどの課題に直面しています。薬剤耐性結核の管理の複雑さや治療期間の長さも市場成長の妨げとなっています。規制の複雑さや国によって異なる政府の方針は、新しい治療法のイントロダクションを遅らせる可能性があります。

市場機会：

結核菌治療市場には技術革新の大きな機会が存在します。分子生物学と遺伝子工学の進歩は、薬剤耐性結核株に対してより有効な新しい治療法を開発する可能性を提供します。官民パートナーシップや国際的な協力関係により研究開発努力が加速される一方、公衆衛生キャンペーンを強化することで認知度を高め、早期発見と治療プロトコルの遵守を向上させることができます。

本レポートで扱う主な質問

  • 2024年から2032年までの結核菌治療市場の予想CAGRは？
  • 結核菌治療市場の成長を促進する主な要因は何か？
  • 最大の市場シェアを占める治療様式は何か？
  • 世界の結核菌治療市場における主要プレイヤーは？
  • 競合を維持するために主要企業はどのような戦略を採用しているか？

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場範囲/ 分類
  • 市場の定義/ 範囲/ 制限
  • 包含と除外

第3章 主要な市場動向

  • 市場に影響を与える主な動向
  • 製品イノベーション/開発動向

第4章 主要な成功要因

  • 地域別の疾病疫学
  • 規制シナリオ
  • PESTLE分析
  • ポーターの分析
  • メーカー別の主なプロモーション戦略
  • サプライチェーン分析

第5章 市場背景

  • マクロ経済要因
  • 予測要因 - 関連性と影響
  • 市場力学

第6章 COVID-19危機分析

  • COVID-19と影響分析
    • 疾患別の収益
    • 治療タイプ別の収益
    • 投与経路別の収益
    • 流通チャネル別の収益
    • 国別の収益
  • 2024年の市場シナリオ

第7章 世界の結核菌治療市場の需要分析

  • 過去の市場価値分析（2019年～2023年）
  • 現在および将来の市場価値予測（2024年～2032年）
    • 前年比成長動向分析
    • 絶対額の機会分析

第8章 世界の結核菌治療市場分析：疾患別

  • イントロダクション/主な調査結果
  • 過去の市場規模分析：疾患別（2019年～2023年）
  • 現在および将来の市場規模分析と予測：疾患別（2024年～2032年）
    • 潜在性結核
    • 活動性結核
  • 疾患別の市場魅力度分析

第9章 世界の結核菌治療市場分析：治療タイプ別

  • イントロダクション/主な調査結果
  • 過去の市場規模分析：治療タイプ別（2019年～2023年）
  • 現在および将来の市場規模分析と予測：治療タイプ別（2024年～2032年）
    • 第一選択薬
    • 第二選択薬
  • 治療タイプ別の市場魅力度分析

第10章 世界の結核菌治療市場分析：投与経路別

  • イントロダクション/主な調査結果
  • 過去の市場規模分析：投与経路別（2019年～2023年）
  • 現在および将来の市場規模分析と予測：投与経路別（2024年～2032年）
    • 経口
    • 静脈内
    • 筋肉内
  • 投与経路別の市場魅力度分析

第11章 世界の結核菌治療市場分析：流通チャネル別

  • イントロダクション/主な調査結果
  • 過去の市場規模分析：流通チャネル別（2019年～2023年）
  • 現在および将来の市場規模分析と予測：流通チャネル別（2024年～2032年）
    • 病院薬局
    • オンライン薬局
    • 小売薬局
    • 法人および個人向け販売
  • 流通チャネル別の市場魅力度分析

第12章 世界の結核菌治療市場分析：地域別

  • イントロダクション
  • 過去の市場規模分析：地域別（2019年～2023年）
  • 現在および将来の市場規模分析と予測：地域別（2024年～2032年）
    • 北米
    • ラテンアメリカ
    • 欧州
    • 東アジア
    • 南アジア
    • オセアニア
    • 中東・アフリカ
  • 地域別の市場魅力度分析

第13章 北米の結核菌治療市場分析

第14章 ラテンアメリカの結核菌治療市場分析

第15章 欧州の結核菌治療市場分析

第16章 南アジアの結核菌治療市場分析

第17章 東アジアの結核菌治療市場分析

第18章 オセアニアの結核菌治療市場分析

第19章 中東・アフリカの結核菌治療市場分析

第20章 市場構造分析

  • 企業階層別市場分析
  • 主要企業の市場シェア分析
  • 市場プレゼンス分析

第21章 競合分析

  • 競合ダッシュボード
  • 競合ベンチマーク
  • 競合の詳細
    • AstraZeneca
    • Johnson &Johnson Private Limited
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd.
    • Mylan NV
    • Teva Pharmaceutical Industries Ltd.
    • Sanofi
    • Novartis AG
    • Sun Pharmaceutical Industries Ltd.
    • Aurobindo Pharma
    • Lupin
    • Allergan
    • Merck &Co., Inc.
    • Pfizer Inc.
    • GlaxoSmithKline plc
    • Hikma Pharmaceuticals PLC
    • Cipla Inc.
    • Endo International plc
    • Otsuka Pharmaceutical Co., Ltd.
    • STI Pharma, LLC

第22章 前提と頭字語

第23章 調査手法

目次
Product Code: PMRREP33190

The Mycobacterium Tuberculosis Treatment Market report by Persistence Market Research provides an in-depth analysis of the market trends, growth drivers, challenges, and prospective innovations spanning from 2024 to 2032. It offers insights into the current landscape and future projections of the market.

The global market for Mycobacterium tuberculosis treatment is expected to achieve a compound annual growth rate (CAGR) of 1.2% from USD 2.13 billion in 2024 to USD 2.40 billion by 2032.

Key Insights:

  • Estimated Market Size (2024): USD 2.13 Billion
  • Projected Market Size (2032): USD 2.40 Billion
  • Global Market Growth Rate (CAGR 2024 to 2032): 1.2%

Mycobacterium Tuberculosis Treatment Market - Report Scope:

Mycobacterium tuberculosis is the bacterium that causes tuberculosis (TB), primarily affecting the lungs but can invade other organs. This report focuses on the drivers promoting the demand for TB treatment, including the global rise in TB cases, increased funding for TB research, and enhancements in diagnostic technologies.

Market Growth Drivers:

The demand for TB treatment is escalating due to several factors. The increase in TB cases globally, enhanced screening and diagnostic measures, and the development of faster-acting and more effective drug regimens drive this growth. The rise of drug-resistant TB forms has spurred research into novel treatment approaches, including combination therapies and longer-term vaccine strategies. Additionally, global health initiatives and funding for TB programs significantly propel market expansion.

Market Restraints:

The Mycobacterium Tuberculosis Treatment Market faces challenges such as the high cost of advanced TB drugs, limited access to medical facilities in low-income countries, and significant rates of treatment non-compliance. The complexity of managing drug-resistant TB and the long duration of treatment also hinder market growth. Regulatory complexities and varying government policies across countries can delay the introduction of new treatments.

Market Opportunities:

Significant opportunities exist for innovation within the TB treatment market. Advances in molecular biology and genetic engineering offer potential for developing new treatments that are more effective against drug-resistant strains of TB. Public-private partnerships and international collaborations can accelerate research and development efforts, while increasing public health campaigns can raise awareness and improve early detection and compliance with treatment protocols.

Key Questions Addressed in the Report:

  • What is the Expected CAGR of the Mycobacterium Tuberculosis Treatment Market from 2024 to 2032?
  • What are the Key Factors Driving the Growth of the Mycobacterium Tuberculosis Treatment Market?
  • Which Treatment Modality Holds the Largest Market Share?
  • Who are the Key Players in the Global Mycobacterium Tuberculosis Treatment Market?
  • What Strategies are Adopted by Leading Companies to Remain Competitive?

Competitive Landscape and Business Strategies:

Key players in the market include Johnson & Johnson, Sanofi, Bayer AG, and GlaxoSmithKline plc. These companies focus on innovations in TB treatment, market penetration in untapped regions, and forming strategic partnerships to stay competitive. For instance, Johnson & Johnson offers Sirturo for multi-drug resistant TB, and Sanofi has been involved in developing booster combinations to enhance treatment efficacy.

Key Companies Profiled:

  • AstraZeneca
  • Johnson & Johnson Private Limited
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd.
  • Aurobindo Pharma
  • Lupin
  • Allergan
  • Merck & Co., Inc.
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Hikma Pharmaceuticals PLC
  • Cipla Inc.
  • Endo International plc
  • Otsuka Pharmaceutical Co., Ltd.
  • STI Pharma, LLC

Mycobacterium Tuberculosis Treatment Market Segmentation:

By Disease Type:

  • Latent TB
  • Active TB

By Treatment Type:

  • First-Line of Drugs
  • Second-Line of Drugs

By Route of Administration:

  • Oral
  • Intravenous
  • Intramuscular

By Distribution Channel:

  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
  • Institutional and Retail Sales

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Market Outlook
  • 1.2. Demand Side Trends
  • 1.3. Supply-Side Trends
  • 1.4. Analysis and Recommendations

2. Market Overview

  • 2.1. Market Coverage / Taxonomy
  • 2.2. Market Definition / Scope / Limitations
  • 2.3. Inclusions & Exclusions

3. Key Market Trends

  • 3.1. Key Trends Impacting the Market
  • 3.2. Product Innovation / Development Trends

4. Key Success Factors

  • 4.1. Disease Epidemiology, By Region
  • 4.2. Regulatory Scenario
  • 4.3. PESTLE Analysis
  • 4.4. Porter's Analysis
  • 4.5. Key Promotional Strategies, by Manufacturers
  • 4.6. Supply Chain Analysis

5. Market Background

  • 5.1. Macro-Economic Factors
    • 5.1.1. Global GDP Growth Outlook
    • 5.1.2. Global Healthcare Expenditure
    • 5.1.3. Global Infectious Disease Treatment Market
  • 5.2. Forecast Factors - Relevance & Impact
    • 5.2.1. Growing Burden of Tuberculosis Disease
    • 5.2.2. Increasing Research and Development Activities
    • 5.2.3. Adoption of Different Treatments for Infectious Disease
    • 5.2.4. Rising Government Support
    • 5.2.5. Increasing FDA Approvals of New Drugs
    • 5.2.6. Strategic Mergers and Acquisitions Among Local Manufacturers
  • 5.3. Market Dynamics
    • 5.3.1. Drivers
    • 5.3.2. Restraints
    • 5.3.3. Opportunity Analysis

6. COVID-19 Crisis Analysis

  • 6.1. COVID-19 and Impact Analysis
    • 6.1.1. Revenue By Disease Type
    • 6.1.2. Revenue By Treatment Type
    • 6.1.3. Revenue By Route of Administration
    • 6.1.4. Revenue By Distribution Channel
    • 6.1.5. Revenue By Country
  • 6.2. 2024 Market Scenario

7. Global Mycobacterium Tuberculosis Treatment Market Demand (in Value or Size in US$ Mn) Analysis 2019-2023 and Forecast, 2024-2032

  • 7.1. Historical Market Value (US$ Mn) Analysis, 2019-2023
  • 7.2. Current and Future Market Value (US$ Mn) Projections, 2024-2032
    • 7.2.1. Y-o-Y Growth Trend Analysis
    • 7.2.2. Absolute $ Opportunity Analysis

8. Global Mycobacterium Tuberculosis Treatment Market Analysis 2019-2023 and Forecast 2024-2032, By Disease Type

  • 8.1. Introduction / Key Findings
  • 8.2. Historical Market Size (US$ Mn) Analysis By Disease Type, 2019-2023
  • 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Disease Type, 2024-2032
    • 8.3.1. Latent TB
    • 8.3.2. Active TB
  • 8.4. Market Attractiveness Analysis By Disease Type

9. Global Mycobacterium Tuberculosis Treatment Market Analysis 2019-2023 and Forecast 2024-2032, By Treatment Type

  • 9.1. Introduction / Key Findings
  • 9.2. Historical Market Size (US$ Mn) Analysis By Treatment Type, 2019-2023
  • 9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Treatment Type, 2024-2032
    • 9.3.1. First-Line of Drugs
    • 9.3.2. Second-Line of Drugs
  • 9.4. Market Attractiveness Analysis By Treatment Type

10. Global Mycobacterium Tuberculosis Treatment Market Analysis 2019-2023 and Forecast 2024-2032, By Route of Administration

  • 10.1. Introduction / Key Findings
  • 10.2. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2019-2023
  • 10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Route of Administration, 2024-2032
    • 10.3.1. Oral
    • 10.3.2. Intravenous
    • 10.3.3. Intramuscular
  • 10.4. Market Attractiveness Analysis By Route of Administration

11. Global Mycobacterium Tuberculosis Treatment Market Analysis 2019-2023 and Forecast 2024-2032, By Distribution Channel

  • 11.1. Introduction / Key Findings
  • 11.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2019-2023
  • 11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2024-2032
    • 11.3.1. Hospital Pharmacies
    • 11.3.2. Online Pharmacies
    • 11.3.3. Retail Pharmacies
    • 11.3.4. Institutional and Retail Sales
  • 11.4. Market Attractiveness Analysis By Distribution Channel

12. Global Mycobacterium Tuberculosis Treatment Market Analysis 2019-2023 and Forecast 2024-2032, by Region

  • 12.1. Introduction
  • 12.2. Historical Market Size (US$ Mn) Analysis, By Region, 2019-2023
  • 12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Region, 2024-2032
    • 12.3.1. North America
    • 12.3.2. Latin America
    • 12.3.3. Europe
    • 12.3.4. East Asia
    • 12.3.5. South Asia
    • 12.3.6. Oceania
    • 12.3.7. Middle East and Africa (MEA)
  • 12.4. Market Attractiveness Analysis By Region

13. North America Mycobacterium Tuberculosis Treatment Market Analysis 2019-2023 and Forecast 2024-2032

  • 13.1. Introduction
  • 13.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
  • 13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast, By Market Taxonomy, 2024-2032
    • 13.3.1. By Country
      • 13.3.1.1. U.S.
      • 13.3.1.2. Canada
    • 13.3.2. By Disease Type
    • 13.3.3. By Treatment Type
    • 13.3.4. By Route of Administration
    • 13.3.5. By Distribution Channel
  • 13.4. Market Attractiveness Analysis
    • 13.4.1. By Country
    • 13.4.2. By Disease Type
    • 13.4.3. By Treatment Type
    • 13.4.4. By Route of Administration
    • 13.4.5. By Distribution Channel
  • 13.5. Market Trends
  • 13.6. Key Market Participants - Intensity Mapping
  • 13.7. Drivers and Restraints - Impact Analysis
  • 13.8. Country Level Analysis & Forecast
    • 13.8.1. U.S. Mycobacterium Tuberculosis Treatment Market Analysis
      • 13.8.1.1. Introduction
      • 13.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.1.2.1. By Disease Type
        • 13.8.1.2.2. By Treatment Type
        • 13.8.1.2.3. By Route of Administration
        • 13.8.1.2.4. By Distribution Channel
    • 13.8.2. Canada Mycobacterium Tuberculosis Treatment Market Analysis
      • 13.8.2.1. Introduction
      • 13.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.2.2.1. By Disease Type
        • 13.8.2.2.2. By Treatment Type
        • 13.8.2.2.3. By Route of Administration
        • 13.8.2.2.4. By Distribution Channel

14. Latin America Mycobacterium Tuberculosis Treatment Market Analysis 2019-2023 and Forecast 2024-2032

  • 14.1. Introduction
  • 14.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
  • 14.3. Current and Future Market Size (US$ Mn) Analysis and Forecast, By Market Taxonomy, 2024-2032
    • 14.3.1. By Country
      • 14.3.1.1. Brazil
      • 14.3.1.2. Mexico
      • 14.3.1.3. Rest of Latin America
    • 14.3.2. By Disease Type
    • 14.3.3. By Treatment Type
    • 14.3.4. By Route of Administration
    • 14.3.5. By Distribution Channel
  • 14.4. Market Attractiveness Analysis
    • 14.4.1. By Country
    • 14.4.2. By Disease Type
    • 14.4.3. By Treatment Type
    • 14.4.4. By Route of Administration
    • 14.4.5. By Distribution Channel
  • 14.5. Market Trends
  • 14.6. Key Market Participants - Intensity Mapping
  • 14.7. Drivers and Restraints - Impact Analysis
  • 14.8. Country Level Analysis & Forecast
    • 14.8.1. Brazil Mycobacterium Tuberculosis Treatment Market Analysis
      • 14.8.1.1. Introduction
      • 14.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.1.2.1. By Disease Type
        • 14.8.1.2.2. By Treatment Type
        • 14.8.1.2.3. By Route of Administration
        • 14.8.1.2.4. By Distribution Channel
    • 14.8.2. Argentina Mycobacterium Tuberculosis Treatment Market Analysis
      • 14.8.2.1. Introduction
      • 14.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.2.2.1. By Disease Type
        • 14.8.2.2.2. By Treatment Type
        • 14.8.2.2.3. By Route of Administration
        • 14.8.2.2.4. Distribution Channel
    • 14.8.3. Mexico Mycobacterium Tuberculosis Treatment Market Analysis
      • 14.8.3.1. Introduction
      • 14.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.3.2.1. By Disease Type
        • 14.8.3.2.2. By Treatment Type
        • 14.8.3.2.3. By Route of Administration
        • 14.8.3.2.4. By Distribution Channel

15. Europe Mycobacterium Tuberculosis Treatment Market Analysis 2019-2023 and Forecast 2024-2032

  • 15.1. Introduction
  • 15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
  • 15.3. Current and Future Market Size (US$ Mn) Analysis and Forecast, By Market Taxonomy, 2024-2032
    • 15.3.1. By Country
      • 15.3.1.1. Germany
      • 15.3.1.2. Italy
      • 15.3.1.3. France
      • 15.3.1.4. U.K.
      • 15.3.1.5. Spain
      • 15.3.1.6. BENELUX
      • 15.3.1.7. Nordic Countries
      • 15.3.1.8. Russia
      • 15.3.1.9. Rest of Europe
    • 15.3.2. By Disease Type
    • 15.3.3. By Treatment Type
    • 15.3.4. By Route of Administration
    • 15.3.5. By Distribution Channel
  • 15.4. Market Attractiveness Analysis
    • 15.4.1. By Country
    • 15.4.2. By Disease Type
    • 15.4.3. By Treatment Type
    • 15.4.4. By Route of Administration
    • 15.4.5. By Distribution Channel
  • 15.5. Market Trends
  • 15.6. Key Market Participants - Intensity Mapping
  • 15.7. Drivers and Restraints - Impact Analysis
  • 15.8. Country Level Analysis & Forecast
    • 15.8.1. Germany Mycobacterium Tuberculosis Treatment Market Analysis
      • 15.8.1.1. Introduction
      • 15.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.1.2.1. By Disease Type
        • 15.8.1.2.2. By Treatment Type
        • 15.8.1.2.3. By Route of Administration
        • 15.8.1.2.4. By Distribution Channel
    • 15.8.2. France Mycobacterium Tuberculosis Treatment Market Analysis
      • 15.8.2.1. Introduction
      • 15.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.2.2.1. By Disease Type
        • 15.8.2.2.2. By Treatment Type
        • 15.8.2.2.3. By Route of Administration
        • 15.8.2.2.4. By Distribution Channel
    • 15.8.3. Italy Mycobacterium Tuberculosis Treatment Market Analysis
      • 15.8.3.1. Introduction
      • 15.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.3.2.1. By Disease Type
        • 15.8.3.2.2. By Treatment Type
        • 15.8.3.2.3. By Route of Administration
        • 15.8.3.2.4. By Distribution Channel
    • 15.8.4. Spain Mycobacterium Tuberculosis Treatment Market Analysis
      • 15.8.4.1. Introduction
      • 15.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.4.2.1. By Disease Type
        • 15.8.4.2.2. By Treatment Type
        • 15.8.4.2.3. By Route of Administration
        • 15.8.4.2.4. By Distribution Channel
    • 15.8.5. U.K. Mycobacterium Tuberculosis Treatment Market Analysis
      • 15.8.5.1. Introduction
      • 15.8.5.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.5.2.1. By Disease Type
        • 15.8.5.2.2. By Treatment Type
        • 15.8.5.2.3. By Route of Administration
        • 15.8.5.2.4. By Distribution Channel
    • 15.8.6. Benelux Union Mycobacterium Tuberculosis Treatment Market Analysis
      • 15.8.6.1. Introduction
      • 15.8.6.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.6.2.1. By Disease Type
        • 15.8.6.2.2. By Treatment Type
        • 15.8.6.2.3. By Route of Administration
        • 15.8.6.2.4. By Distribution Channel
    • 15.8.7. Nordic Countries Mycobacterium Tuberculosis Treatment Market Analysis
      • 15.8.7.1. Introduction
      • 15.8.7.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.7.2.1. By Disease Type
        • 15.8.7.2.2. By Treatment Type
        • 15.8.7.2.3. By Route of Administration
        • 15.8.7.2.4. By Distribution Channel
    • 15.8.8. Russia Mycobacterium Tuberculosis Treatment Market Analysis
      • 15.8.8.1. Introduction
      • 15.8.8.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.8.2.1. By Disease Type
        • 15.8.8.2.2. By Treatment Type
        • 15.8.8.2.3. By Route of Administration
        • 15.8.8.2.4. By Distribution Channel

16. South Asia Mycobacterium Tuberculosis Treatment Market Analysis 2019-2023 and Forecast 2024-2032

  • 16.1. Introduction
  • 16.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
  • 16.3. Current and Future Market Size (US$ Mn) Analysis and Forecast, By Market Taxonomy, 2024-2032
    • 16.3.1. By Country
      • 16.3.1.1. India
      • 16.3.1.2. Thailand
      • 16.3.1.3. Indonesia
      • 16.3.1.4. Malaysia
      • 16.3.1.5. Rest of South Asia
    • 16.3.2. By Disease Type
    • 16.3.3. By Treatment Type
    • 16.3.4. By Route of Administration
    • 16.3.5. By Distribution Channel
  • 16.4. Market Attractiveness Analysis
    • 16.4.1. By Country
    • 16.4.2. By Disease Type
    • 16.4.3. By Treatment Type
    • 16.4.4. By Route of Administration
    • 16.4.5. By Distribution Channel
  • 16.5. Market Trends
  • 16.6. Key Market Participants - Intensity Mapping
  • 16.7. Drivers and Restraints - Impact Analysis
  • 16.8. Country Level Analysis & Forecast
    • 16.8.1. India Mycobacterium Tuberculosis Treatment Market Analysis
      • 16.8.1.1. Introduction
      • 16.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.1.2.1. By Disease Type
        • 16.8.1.2.2. By Treatment Type
        • 16.8.1.2.3. By Route of Administration
        • 16.8.1.2.4. By Distribution Channel
    • 16.8.2. Indonesia Mycobacterium Tuberculosis Treatment Market Analysis
      • 16.8.2.1. Introduction
      • 16.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.2.2.1. By Disease Type
        • 16.8.2.2.2. By Treatment Type
        • 16.8.2.2.3. By Route of Administration
        • 16.8.2.2.4. By Distribution Channel
    • 16.8.3. Malaysia Mycobacterium Tuberculosis Treatment Market Analysis
      • 16.8.3.1. Introduction
      • 16.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.3.2.1. By Disease Type
        • 16.8.3.2.2. By Treatment Type
        • 16.8.3.2.3. By Route of Administration
        • 16.8.3.2.4. By Distribution Channel
        • 16.8.3.2.5. By Distribution Channel
    • 16.8.4. Thailand Mycobacterium Tuberculosis Treatment Market Analysis
      • 16.8.4.1. Introduction
      • 16.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.4.2.1. By Disease Type
        • 16.8.4.2.2. By Treatment Type
        • 16.8.4.2.3. By Route of Administration
        • 16.8.4.2.4. By Distribution Channel

17. East Asia Mycobacterium Tuberculosis Treatment Market Analysis 2019-2023 and Forecast 2024-2032

  • 17.1. Introduction
  • 17.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
  • 17.3. Current and Future Market Size (US$ Mn) Analysis and Forecast, By Market Taxonomy, 2024-2032
    • 17.3.1. By Country
      • 17.3.1.1. China
      • 17.3.1.2. Japan
      • 17.3.1.3. South Korea
    • 17.3.2. By Disease Type
    • 17.3.3. By Treatment Type
    • 17.3.4. By Route of Administration
    • 17.3.5. By Distribution Channel
  • 17.4. Market Attractiveness Analysis
    • 17.4.1. By Country
    • 17.4.2. By Disease Type
    • 17.4.3. By Treatment Type
    • 17.4.4. By Route of Administration
    • 17.4.5. By Distribution Channel
  • 17.5. Market Trends
  • 17.6. Key Market Participants - Intensity Mapping
  • 17.7. Drivers and Restraints - Impact Analysis
  • 17.8. Country Level Analysis & Forecast
    • 17.8.1. China Mycobacterium Tuberculosis Treatment Market Analysis
      • 17.8.1.1. Introduction
      • 17.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.1.2.1. By Disease Type
        • 17.8.1.2.2. By Treatment Type
        • 17.8.1.2.3. By Route of Administration
        • 17.8.1.2.4. By Distribution Channel
    • 17.8.2. Japan Mycobacterium Tuberculosis Treatment Market Analysis
      • 17.8.2.1. Introduction
      • 17.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.2.2.1. By Disease Type
        • 17.8.2.2.2. By Treatment Type
        • 17.8.2.2.3. By Route of Administration
        • 17.8.2.2.4. By Distribution Channel
    • 17.8.3. South Korea Mycobacterium Tuberculosis Treatment Market Analysis
      • 17.8.3.1. Introduction
      • 17.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.3.2.1. By Disease Type
        • 17.8.3.2.2. By Treatment Type
        • 17.8.3.2.3. By Route of Administration
        • 17.8.3.2.4. By Distribution Channel

18. Oceania Mycobacterium Tuberculosis Treatment Market Analysis 2019-2023 and Forecast 2024-2032

  • 18.1. Introduction
  • 18.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
  • 18.3. Current and Future Market Size (US$ Mn) Analysis and Forecast, By Market Taxonomy, 2024-2032
    • 18.3.1. By Country
      • 18.3.1.1. Australia
      • 18.3.1.2. New Zealand
    • 18.3.2. By Disease Type
    • 18.3.3. By Treatment Type
    • 18.3.4. By Route of Administration
    • 18.3.5. By Distribution Channel
  • 18.4. Market Attractiveness Analysis
    • 18.4.1. By Country
    • 18.4.2. By Disease Type
    • 18.4.3. By Treatment Type
    • 18.4.4. By Route of Administration
    • 18.4.5. By Distribution Channel
  • 18.5. Market Trends
  • 18.6. Key Market Participants - Intensity Mapping
  • 18.7. Drivers and Restraints - Impact Analysis
  • 18.8. Country Level Analysis & Forecast
    • 18.8.1. Australia Mycobacterium Tuberculosis Treatment Market Analysis
      • 18.8.1.1. Introduction
      • 18.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 18.8.1.2.1. By Disease Type
        • 18.8.1.2.2. By Treatment Type
        • 18.8.1.2.3. By Route of Administration
        • 18.8.1.2.4. By Distribution Channel
    • 18.8.2. New Zealand Mycobacterium Tuberculosis Treatment Market Analysis
      • 18.8.2.1. Introduction
      • 18.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 18.8.2.2.1. By Disease Type
        • 18.8.2.2.2. By Treatment Type
        • 18.8.2.2.3. By Route of Administration
        • 18.8.2.2.4. By Distribution Channel

19. Middle East and Africa (MEA) Mycobacterium Tuberculosis Treatment Market Analysis 2019-2023 and Forecast 2024-2032

  • 19.1. Introduction
  • 19.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
  • 19.3. Current and Future Market Size (US$ Mn) Analysis and Forecast, By Market Taxonomy, 2024-2032
    • 19.3.1. By Country
      • 19.3.1.1. GCC Countries
      • 19.3.1.2. Turkey
      • 19.3.1.3. North Africa
      • 19.3.1.4. South Africa
      • 19.3.1.5. Rest of Middle East and Africa
    • 19.3.2. By Disease Type
    • 19.3.3. By Treatment Type
    • 19.3.4. By Route of Administration
    • 19.3.5. By Distribution Channel
  • 19.4. Market Attractiveness Analysis
    • 19.4.1. By Country
    • 19.4.2. By Disease Type
    • 19.4.3. By Treatment Type
    • 19.4.4. By Route of Administration
    • 19.4.5. By Distribution Channel
  • 19.5. Market Trends
  • 19.6. Key Market Participants - Intensity Mapping
  • 19.7. Drivers and Restraints - Impact Analysis
  • 19.8. Country Level Analysis & Forecast
    • 19.8.1. GCC Countries Mycobacterium Tuberculosis Treatment Market Analysis
      • 19.8.1.1. Introduction
      • 19.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 19.8.1.2.1. By Disease Type
        • 19.8.1.2.2. By Treatment Type
        • 19.8.1.2.3. By Route of Administration
        • 19.8.1.2.4. By Distribution Channel
    • 19.8.2. Turkey Mycobacterium Tuberculosis Treatment Market Analysis
      • 19.8.2.1. Introduction
      • 19.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 19.8.2.2.1. By Disease Type
        • 19.8.2.2.2. By Treatment Type
        • 19.8.2.2.3. By Route of Administration
        • 19.8.2.2.4. By Distribution Channel
    • 19.8.3. North Africa Mycobacterium Tuberculosis Treatment Market Analysis
      • 19.8.3.1. Introduction
      • 19.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 19.8.3.2.1. By Disease Type
        • 19.8.3.2.2. By Treatment Type
        • 19.8.3.2.3. By Route of Administration
        • 19.8.3.2.4. By Distribution Channel
    • 19.8.4. South Africa Mycobacterium Tuberculosis Treatment Market Analysis
      • 19.8.4.1. Introduction
      • 19.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 19.8.4.2.1. By Disease Type
        • 19.8.4.2.2. By Treatment Type
        • 19.8.4.2.3. By Route of Administration
        • 19.8.4.2.4. By Distribution Channel

20. Market Structure Analysis

  • 20.1. Market Analysis by Tier of Companies
  • 20.2. Market Share Analysis of Top Players
  • 20.3. Market Presence Analysis
    • 20.3.1. Regional Footprint Analysis
    • 20.3.2. Channel Footprint Analysis

21. Competition Analysis

  • 21.1. Competition Dashboard
  • 21.2. Competition Benchmarking
  • 21.3. Competition Deep Dive
    • 21.3.1. AstraZeneca
      • 21.3.1.1. Overview
      • 21.3.1.2. Product Portfolio
      • 21.3.1.3. Key Financials
      • 21.3.1.4. SWOT Analysis
      • 21.3.1.5. Sales Footprint
      • 21.3.1.6. Strategy Overview
      • 21.3.1.7. Key Developments
        • 21.3.1.7.1. Marketing Strategies
        • 21.3.1.7.2. Channel Strategies
    • 21.3.2. Johnson & Johnson Private Limited
      • 21.3.2.1. Overview
      • 21.3.2.2. Product Portfolio
      • 21.3.2.3. Key Financials
      • 21.3.2.4. SWOT Analysis
      • 21.3.2.5. Sales Footprint
      • 21.3.2.6. Strategy Overview
      • 21.3.2.7. Key Developments
        • 21.3.2.7.1. Marketing Strategies
        • 21.3.2.7.2. Channel Strategies
    • 21.3.3. Eli Lilly and Company
      • 21.3.3.1. Overview
      • 21.3.3.2. Product Portfolio
      • 21.3.3.3. Key Financials
      • 21.3.3.4. SWOT Analysis
      • 21.3.3.5. Sales Footprint
      • 21.3.3.6. Strategy Overview
      • 21.3.3.7. Key Developments
        • 21.3.3.7.1. Marketing Strategies
        • 21.3.3.7.2. Channel Strategies
    • 21.3.4. F. Hoffmann-La Roche Ltd.
      • 21.3.4.1. Overview
      • 21.3.4.2. Product Portfolio
      • 21.3.4.3. Key Financials
      • 21.3.4.4. SWOT Analysis
      • 21.3.4.5. Sales Footprint
      • 21.3.4.6. Strategy Overview
      • 21.3.4.7. Key Developments
        • 21.3.4.7.1. Marketing Strategies
        • 21.3.4.7.2. Channel Strategies
    • 21.3.5. Mylan N.V.
      • 21.3.5.1. Overview
      • 21.3.5.2. Product Portfolio
      • 21.3.5.3. Key Financials
      • 21.3.5.4. SWOT Analysis
      • 21.3.5.5. Sales Footprint
      • 21.3.5.6. Strategy Overview
      • 21.3.5.7. Key Developments
        • 21.3.5.7.1. Marketing Strategies
        • 21.3.5.7.2. Channel Strategies
    • 21.3.6. Teva Pharmaceutical Industries Ltd.
      • 21.3.6.1. Overview
      • 21.3.6.2. Product Portfolio
      • 21.3.6.3. Key Financials
      • 21.3.6.4. SWOT Analysis
      • 21.3.6.5. Sales Footprint
      • 21.3.6.6. Strategy Overview
      • 21.3.6.7. Key Developments
        • 21.3.6.7.1. Marketing Strategies
        • 21.3.6.7.2. Channel Strategies
    • 21.3.7. Sanofi
      • 21.3.7.1. Overview
      • 21.3.7.2. Product Portfolio
      • 21.3.7.3. Key Financials
      • 21.3.7.4. SWOT Analysis
      • 21.3.7.5. Sales Footprint
      • 21.3.7.6. Strategy Overview
      • 21.3.7.7. Key Developments
        • 21.3.7.7.1. Marketing Strategies
        • 21.3.7.7.2. Channel Strategies
    • 21.3.8. Novartis AG
      • 21.3.8.1. Overview
      • 21.3.8.2. Product Portfolio
      • 21.3.8.3. Key Financials
      • 21.3.8.4. SWOT Analysis
      • 21.3.8.5. Sales Footprint
      • 21.3.8.6. Strategy Overview
      • 21.3.8.7. Key Developments
        • 21.3.8.7.1. Marketing Strategies
        • 21.3.8.7.2. Channel Strategies
    • 21.3.9. Sun Pharmaceutical Industries Ltd.
      • 21.3.9.1. Overview
      • 21.3.9.2. Product Portfolio
      • 21.3.9.3. Key Financials
      • 21.3.9.4. SWOT Analysis
      • 21.3.9.5. Sales Footprint
      • 21.3.9.6. Strategy Overview
      • 21.3.9.7. Key Developments
        • 21.3.9.7.1. Marketing Strategies
        • 21.3.9.7.2. Channel Strategies
    • 21.3.10. Aurobindo Pharma
      • 21.3.10.1. Overview
      • 21.3.10.2. Product Portfolio
      • 21.3.10.3. Key Financials
      • 21.3.10.4. SWOT Analysis
      • 21.3.10.5. Sales Footprint
      • 21.3.10.6. Strategy Overview
      • 21.3.10.7. Key Developments
        • 21.3.10.7.1. Marketing Strategies
        • 21.3.10.7.2. Channel Strategies
    • 21.3.11. Lupin
      • 21.3.11.1. Overview
      • 21.3.11.2. Product Portfolio
      • 21.3.11.3. Key Financials
      • 21.3.11.4. SWOT Analysis
      • 21.3.11.5. Sales Footprint
      • 21.3.11.6. Strategy Overview
      • 21.3.11.7. Key Developments
        • 21.3.11.7.1. Marketing Strategies
        • 21.3.11.7.2. Channel Strategies
    • 21.3.12. Allergan
      • 21.3.12.1. Overview
      • 21.3.12.2. Product Portfolio
      • 21.3.12.3. Key Financials
      • 21.3.12.4. SWOT Analysis
      • 21.3.12.5. Sales Footprint
      • 21.3.12.6. Strategy Overview
      • 21.3.12.7. Key Developments
        • 21.3.12.7.1. Marketing Strategies
        • 21.3.12.7.2. Channel Strategies
    • 21.3.13. Merck & Co., Inc.
      • 21.3.13.1. Overview
      • 21.3.13.2. Product Portfolio
      • 21.3.13.3. Key Financials
      • 21.3.13.4. SWOT Analysis
      • 21.3.13.5. Sales Footprint
      • 21.3.13.6. Strategy Overview
      • 21.3.13.7. Key Developments
        • 21.3.13.7.1. Marketing Strategies
        • 21.3.13.7.2. Channel Strategies
    • 21.3.14. Pfizer Inc.
      • 21.3.14.1. Overview
      • 21.3.14.2. Product Portfolio
      • 21.3.14.3. Key Financials
      • 21.3.14.4. SWOT Analysis
      • 21.3.14.5. Sales Footprint
      • 21.3.14.6. Strategy Overview
      • 21.3.14.7. Key Developments
        • 21.3.14.7.1. Marketing Strategies
        • 21.3.14.7.2. Channel Strategies
    • 21.3.15. GlaxoSmithKline plc
      • 21.3.15.1. Overview
      • 21.3.15.2. Product Portfolio
      • 21.3.15.3. Key Financials
      • 21.3.15.4. SWOT Analysis
      • 21.3.15.5. Sales Footprint
      • 21.3.15.6. Strategy Overview
      • 21.3.15.7. Key Developments
        • 21.3.15.7.1. Marketing Strategies
        • 21.3.15.7.2. Channel Strategies
    • 21.3.16. Hikma Pharmaceuticals PLC
      • 21.3.16.1. Overview
      • 21.3.16.2. Product Portfolio
      • 21.3.16.3. Key Financials
      • 21.3.16.4. SWOT Analysis
      • 21.3.16.5. Sales Footprint
      • 21.3.16.6. Strategy Overview
      • 21.3.16.7. Key Developments
        • 21.3.16.7.1. Marketing Strategies
        • 21.3.16.7.2. Channel Strategies
    • 21.3.17. Cipla Inc.
      • 21.3.17.1. Overview
      • 21.3.17.2. Product Portfolio
      • 21.3.17.3. Key Financials
      • 21.3.17.4. SWOT Analysis
      • 21.3.17.5. Sales Footprint
      • 21.3.17.6. Strategy Overview
      • 21.3.17.7. Key Developments
        • 21.3.17.7.1. Marketing Strategies
        • 21.3.17.7.2. Channel Strategies
    • 21.3.18. Endo International plc
      • 21.3.18.1. Overview
      • 21.3.18.2. Product Portfolio
      • 21.3.18.3. Key Financials
      • 21.3.18.4. SWOT Analysis
      • 21.3.18.5. Sales Footprint
      • 21.3.18.6. Strategy Overview
      • 21.3.18.7. Key Developments
        • 21.3.18.7.1. Marketing Strategies
        • 21.3.18.7.2. Channel Strategies
    • 21.3.19. Otsuka Pharmaceutical Co., Ltd.
      • 21.3.19.1. Overview
      • 21.3.19.2. Product Portfolio
      • 21.3.19.3. Key Financials
      • 21.3.19.4. SWOT Analysis
      • 21.3.19.5. Sales Footprint
      • 21.3.19.6. Strategy Overview
      • 21.3.19.7. Key Developments
        • 21.3.19.7.1. Marketing Strategies
        • 21.3.19.7.2. Channel Strategies
    • 21.3.20. STI Pharma, LLC
      • 21.3.20.1. Overview
      • 21.3.20.2. Product Portfolio
      • 21.3.20.3. Key Financials
      • 21.3.20.4. SWOT Analysis
      • 21.3.20.5. Sales Footprint
      • 21.3.20.6. Strategy Overview
      • 21.3.20.7. Key Developments
        • 21.3.20.7.1. Marketing Strategies
        • 21.3.20.7.2. Channel Strategies

22. Assumptions and Acronyms Used

23. Research Methodology